Report from the 13th annual western Canadian gastrointestinal cancer consensus conference; Calgary, Alberta; September 8-10, 2011

Current Oncology

Volumn 19, Issue 6, 2012, Pages

  Vickers, M M ^a   Pasieka, J ^b   Dixon, E ^b   McEwan, S ^c   McKay, A ^d   Renouf, D ^e   Schellenberg, D ^e   Ruether, D ^a  

^a TOM BAKER CANCER CENTRE   (Canada)

^b FOOTHILLS HOSPITAL   (Canada)

^c CROSS CANCER INSTITUTE   (Canada)

^d HEALTH SCIENCES CENTRE   (Canada)

^e BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

Neuroendocrine tumours; Pancreatic cancer; Radiation; Systemic therapy

Indexed keywords

ANTINEOPLASTIC AGENT; CAPECITABINE; ERLOTINIB; EVEROLIMUS; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; OCTREOTIDE; OXALIPLATIN; PLACEBO; PLATINUM COMPLEX; SUNITINIB; YTTRIUM;

ARTICLE; CANADA; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; DIGESTIVE SYSTEM CANCER; DRUG TOLERABILITY; EVIDENCE BASED MEDICINE; HEALTH CARE PERSONNEL; HUMAN; METASTASIS; NEUROENDOCRINE TUMOR; NEUTROPENIA; PANCREAS CANCER; PANCREAS TUMOR; PATIENT CARE; PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PROGRESSION FREE SURVIVAL; RADIOISOTOPE THERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); STEREOTACTIC RADIOSURGERY; TREATMENT INDICATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

EID: 84870737928     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.19.1167     Document Type: Article

References (87)

1. Canadian Task Force on Preventive Health Care (CTFPHC). Table 2. Levels of Evidence-Research Design Rating [Web page]. London, ON: CTFPHC; 2003. [Available at: http://www.canadiantaskforce.ca/_archive/ctfphc&methods.htm#Table_2; cited June 8, 2012]
2. Rinke A, Müller HH, Schade-Brittinger C, et al. on behalf of the PROMID Study Group. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 2009;27:4656-63.
3. Yao JC, Hassan M, Phan A, et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008;26:3063-72.
4. Reubi JC, Waser B, Schaer JC, Laissue JA. Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur J Nucl Med 2001;28:836-46.
5. Eriksson B, Oberg K. Summing up 15 years of somatostatin analog therapy in neuroendocrine tumors: future outlook. Ann Oncol 1999;10(suppl 2):S31-8.
6. Theodoropoulou M, Zhang J, Laupheimer S, et al. Octreotide, a somatostatin analogue, mediates its antiproliferative action in pituitary tumor cells by altering phosphatidylinositol 3-kinase signaling and inducing Zac1 expression. Cancer Res 2006;66:1576-82.
7. Florio T. Molecular mechanisms of the antiproliferative activity of somatostatin receptors (sstrs) in neuroendocrine tumors. Front Biosci 2008;13:822-40.
8. Plöckinger U, Wiedenmann B. Neuroendocrine tumors. Biotherapy. Best Pract Res Clin Endocrinol Metab 2007;21:145-62.
9. Yao JC, Shah MH, Ito T, et al. on behalf of the RAD001 in Advanced Neuroendocrine Tumors, Third Trial (radiant-3) Study Group. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011;364:514-23.
10. O'Reilly T, McSheehy PM. Biomarker development for the clinical activity of the mtor inhibitor everolimus (RAD001): processes, limitations, and further proposals. Transl Oncol 2010;3:65-79.
11. Meric-Bernstam F, Gonzalez-Angulo AM. Targeting the mtor signaling network for cancer therapy. J Clin Oncol 2009;27:2278-87.
12. Faivre S, Kroemer G, Raymond E. Current development of MTOR inhibitors as anticancer agents. Nat Rev Drug Discov 2006;5:671-88.
13. Plank TL, Logginidou H, Klein-Szanto A, Henske EP. The expression of hamartin, the product of the TSC1 gene, in normal human tissues and in TSC1- and TSC2-linked angiomyolipomas. Mod Pathol 1999;12:539-45.
14. Verhoef S, van Diemen-Steenvoorde R, Akkersdijk WL, et al. Malignant pancreatic tumour within the spectrum of tuberous sclerosis complex in childhood. Eur J Pediatr 1999;158:284-7.
15. Eledrisi MS, Stuart CA, Alshanti M. Insulinoma in a patient with tuberous sclerosis: is there an association? Endocr Pract 2002;8:109-12.
16. von Wichert G, Jehle PM, Hoeflich A, et al. Insulin-like growth factor-i is an autocrine regulator of chromogranin A secretion and growth in human neuroendocrine tumor cells. Cancer Res 2000;60:4573-81.
17. Pollak MN, Polychronakos C, Guyda H. Somatostatin analogue sms 201-995 reduces serum igf-i levels in patients with neoplasms potentially dependent on igf-i. Anticancer Res 1989;9:889-91.
18. Moreno A, Akcakanat A, Munsell MF, Soni A, Yao JC, Meric-Bernstam F. Antitumor activity of rapamycin and octreotide as single agents or in combination in neuroendocrine tumors. Endocr Relat Cancer 2008;15:257-66.
19. Yao JC, Phan AT, Chang DZ, et al. Efficacy of RAD001 (everolimus) and octreotide lar in advanced low-to intermediategrade neuroendocrine tumors: results of a phase ii study. J Clin Oncol 2008;26:4311-18.
20. Pavel ME, Hainsworth JD, Baudin E, et al. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (radiant-2): a randomised, placebo-controlled, phase 3 study. Lancet 2011;378:2005-12.
21. Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011;364:501-13.
22. Johannessen CM, Reczek EE, James MF, Brems H, Legius E, Cichowski K. The NF1 tumor suppressor critically regulates tsc2 and mtor. Proc Natl Acad Sci U S A 2005;102:8573-8.
23. Tan CC, Hall RI, Semeraro D, Irons RP, Freeman JG. Ampullary somatostatinoma associated with von Recklinghausen's neurofibromatosis presenting as obstructive jaundice. Eur J Surg Oncol 1996;22:298-301.
24. van Basten JP, van Hoek B, de Bruïne A, Arends JW, Stockbrügger RW. Ampullary carcinoid and neurofibromatosis: case report and review of the literature. Neth J Med 1994;44:202-6.
25. Yoshida A, Hatanaka S, Ohi Y, Umekita Y, Yoshida H. von Recklinghausen's disease associated with somatostatin-rich duodenal carcinoid (somatostatinoma), medullary thyroid carcinoma and diffuse adrenal medullary hyperplasia. Acta Pathol Jpn 1991;41:847-56.
26. Turner HE, Harris AL, Melmed S, Wass JA. Angiogenesis in endocrine tumors. Endocr Rev 2003;24:600-32.
27. Terris B, Scoazec JY, Rubbia L, et al. Expression of vascular endothelial growth factor in digestive neuroendocrine tumours. Histopathology 1998;32:133-8.
28. La Rosa S, Uccella S, Finzi G, Albarello L, Sessa F, Capella C. Localization of vascular endothelial growth factor and its receptors in digestive endocrine tumors: correlation with microvessel density and clinicopathologic features. Hum Pathol 2003;34:18-27.
29. Christofori G, Naik P, Hanahan D. Vascular endothelial growth factor and its receptors, Flt-1 and Flk-1, are expressed in normal pancreatic islets and throughout islet cell tumorigenesis. Mol Endocrinol 1995;9:1760-70.
30. Chaudhry A, Papanicolaou V, Oberg K, Heldin CH, Funa K. Expression of platelet-derived growth factor and its receptors in neuroendocrine tumors of the digestive system. Cancer Res 1992;52:1006-12.
31. Van Gompel JJ, Chen H. Insulin-like growth factor 1 signaling in human gastrointestinal carcinoid tumor cells. Surgery 2004;136:1297-302.
32. Zhang PJ, Furth EE, Cai X, Goldblum JR, Pasha TL, Min KW. The role of beta-catenin, tgf beta 3, NGF2, FGF2, IGFR2, and BMP4 in the pathogenesis of mesenteric sclerosis and angiopathy in midgut carcinoids. Hum Pathol 2004;35:670-4.
33. Koch CA, Gimm O, Vortmeyer AO, et al. Does the expression of c-Kit (CD117) in neuroendocrine tumors represent a target for therapy? Ann N Y Acad Sci 2006;1073:517-26.
34. Krishnamurthy S, Dayal Y. Immunohistochemical expression of transforming growth factor alpha and epidermal growth factor receptor in gastrointestinal carcinoids. Am J Surg Pathol 1997;21:327-33.
35. Halfdanarson TR, Rabe KG, Rubin J, Petersen GM. Pancreatic neuroendocrine tumors (pnets): incidence, prognosis and recent trend toward improved survival. Ann Oncol 2008;19:1727-33.
36. Jensen RT, Delle Fave G. Promising advances in the treatment of malignant pancreatic endocrine tumors. N Engl J Med 2011;364:564-5.
37. Hellman P, Lundström T, Ohrvall U, et al. Effect of surgery on the outcome of midgut carcinoid disease with lymph node and liver metastases. World J Surg 2002;26:991-7.
38. Chambers AJ, Pasieka JL, Dixon E, Rorstad O. The palliative benefit of aggressive surgical intervention for both hepatic and mesenteric metastases from neuroendocrine tumors. Surgery 2008;144:645-51.
39. Norlén O, Stålberg P, Öberg K, et al. Long-term results of surgery for small intestinal neuroendocrine tumors at a tertiary referral center. World J Surg 2012;36:1419-31.
40. Akerström G, Hellman P, Hessman O, Osmak L. Management of midgut carcinoids. J Surg Oncol 2005;89:161-9.
41. Givi B, Pommier SJ, Thompson AK, Diggs BS, Pommier RF. Operative resection of primary carcinoid neoplasms in patients with liver metastases yields significantly better survival. Surgery 2006;140:891-7.
42. Ahmed A, Turner G, King B, et al. Midgut neuroendocrine tumours with liver metastases: results of the ukinets study. Endocr Relat Cancer 2009;16:885-94.
43. Chambers AJ, Pasieka JL, Dixon E, Rorstad O. Role of imaging in the preoperative staging of small bowel neuroendocrine tumors. J Am Coll Surg 2010;211:620-7.
44. Singh S, Law C. Multidisciplinary reference centers: the care of neuroendocrine tumors. J Oncol Pract 2010;6:e11-16.
45. Mayo SC, de Jong MC, Pulitano C, et al. Surgical management of hepatic neuroendocrine tumor metastasis: results from an international multi-institutional analysis. Ann Surg Oncol 2010;17:3129-36.
46. Sarmiento JM, Heywood G, Rubin J, Ilstrup DM, Nagorney DM, Que FG. Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. J Am Coll Surg 2003;197:29-37.
47. Vauthey JN, Dixon E. AHPBA/SSO/SSAT Consensus Conference on Resectable and Borderline Resectable Pancreatic Cancer: rationale and overview of the conference. Ann Surg Oncol 2009;16:1725-6.
48. Crile G Jr. The advantages of bypass operations over radical pancreatoduodenectomy in the treatment of pancreatic carcinoma. Surg Gynecol Obstet 1970;130:1049-53.
49. Cameron JL, Riall TS, Coleman J, Belcher KA. One thousand consecutive pancreaticoduodenectomies. Ann Surg 2006;244:10-15.
50. Tseng JF, Raut CP, Lee JE, et al. Pancreaticoduodenectomy with vascular resection: margin status and survival duration. J Gastrointest Surg 2004;8:935-49.
51. Bockhorn M, Burdelski C, Bogoevski D, Sgourakis G, Yekebas EF, Izbicki JR. Arterial en bloc resection for pancreatic carcinoma. Br J Surg 2011;98:86-92.
52. Katz MH, Pisters PW, Evans DB, et al. Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. J Am Coll Surg 2008;206:833-46.
53. Evans DB, Erickson BA, Ritch P. Borderline resectable pancreatic cancer: definitions and the importance of multimodality therapy. Ann Surg Oncol 2010;17:2803-5.
54. Callery MP, Chang KJ, Fishman EK, et al. Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement. Ann Surg Oncol 2009;16:1727-33.
55. Abrams RA, Lowy AM, O'Reilly EM, Wolff RA, Picozzi VJ, Pisters PW. Combined modality treatment of resectable and borderline resectable pancreas cancer: expert consensus statement. Ann Surg Oncol 2009;16:1751-6.
56. Burris HA 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997;15:2403-13.
57. Moore MJ, Goldstein D, Hamm J, et al. on behalf of the NCIC Clinical Trials Group. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase iii trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007;25:1960-6.
58. Heinemann V, Quietzsch D, Gieseler F, et al. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol 2006;24:3946-52.
59. Colucci G, Giuliani F, Gebbia V, et al. Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase iii study of the Gruppo Oncologia dell'Italia Meridionale. Cancer 2002;94:902-10.
60. Colucci G, Labianca R, Di Costanzo F, et al. on behalf of the Gruppo Oncologico Italia Meridionale (GOIM), the Gruppo Italiano per lo Studio dei Carcinomi dell'Apparato Digerente (GISCAD), and the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC). Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the gip-1 study. J Clin Oncol 2010;28:1645-51.
61. Louvet C, Labianca R, Hammel P, et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and giscad phase iii trial. J Clin Oncol 2005;23:3509-16.
62. Herrmann R, Bodoky G, Ruhstaller T, et al. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. J Clin Oncol 2007;25:2212-17.
63. Cunningham D, Chau I, Stocken DD, et al. Phase iii randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol 2009;27:5513-18.
64. Rocha Lima CM, Green MR, Rotche R, et al. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol 2004;22:3776-83.
65. Oettle H, Richards D, Ramanathan RK, et al. A phase iii trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer. Ann Oncol 2005;16:1639-45.
66. Heinemann V, Labianca R, Hinke A, Louvet C. Increased survival using platinum analog combined with gemcitabine as compared to single-agent gemcitabine in advanced pancreatic cancer: pooled analysis of two randomized trials, the GERCOR/ GISCAD intergroup study and a German multicenter study. Ann Oncol 2007;18:1652-9.
67. Philip PA, Benedetti J, Corless CL, et al. Phase iii study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed Intergroup Trial S0205. J Clin Oncol 2010;28:3605-10.
68. Van Cutsem E, Vervenne WL, Bennouna J, et al. Phase iii trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol 2009;27:2231-7.
69. Moore MJ, Hamm J, Dancey J, et al. on behalf of NCIC Clinical Trials Group. Comparison of gemcitabine versus the matrix metalloproteinase inhibitor bay 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase iii trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2003;21:3296-302.
70. Kindler HL, Niedzwiecki D, Hollis D, et al. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase iii trial of the Cancer and Leukemia Group B (calgb 80303). J Clin Oncol 2010;28:3617-22.
71. Conroy T, Desseigne F, Ychou M, et al. On behalf of the Groupe Tumeurs Digestives of Unicancer and the prodige Intergroup. folfirinox versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011;364:1817-25.
72. Kim R. FOLFIRINOX: a new standard treatment for advanced pancreatic cancer? Lancet Oncol 2011;12:8-9.
73. Philip PA, Mooney M, Jaffe D, et al. Consensus report of the national cancer institute clinical trials planning meeting on pancreas cancer treatment. J Clin Oncol 2009;27:5660-9.
74. Hosein PJ, Kawamura C, Macintyre J, et al. Pilot study of neoadjuvant folfirinox in unresectable locally advanced pancreatic carcinoma [abstract 234]. J Clin Oncol 2011;29(suppl 4):. [Available online at http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=103&abstractID=70687; cited September 13, 2012]
75. Huguet F, Girard N, Guerche CS, Hennequin C, Mornex F, Azria D. Chemoradiotherapy in the management of locally advanced pancreatic carcinoma: a qualitative systematic review. J Clin Oncol 2009;27:2269-77.
76. Hammel P, Huguet F, Van Laethem JL, et al. Randomized multicenter phase iii study in patients with locally advanced adenocarcinoma of the pancreas: gemcitabine with or withoutchemoradiotherapy and with or without erlotinib-LAP 07 study [abstract e14619]. J Clin Oncol 2011;29:. [Available online at http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=83116; cited September 13, 2012]
77. Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. Gastrointestinal Tumor Study Group. J Natl Cancer Inst 1988;80:751-5.
78. Wilkowski R, Boeck S, Ostermaier S, et al. Chemoradiotherapy with concurrent gemcitabine and cisplatin with or without sequential chemotherapy with gemcitabine/cisplatin vs chemoradiotherapy with concurrent 5-fluorouracil in patients with locally advanced pancreatic cancer-a multi-centre randomised phase ii study. Br J Cancer 2009;101:1853-9.
79. Neoptolemos JP, Dunn JA, Stocken DD, et al. on behalf of the European Study Group for Pancreatic Cancer. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet 2001;358:1576-85.
80. Smeenk HG, van Eijck CH, Hop WC, et al. Long-term survival and metastatic pattern of pancreatic and periampullary cancer after adjuvant chemoradiation or observation: long-term results of eortc trial 40891. Ann Surg 2007;246:734-40.
81. Patel M, Hoffe S, Malafa M, et al. Neoadjuvant GTX chemotherapy and IMRT-based chemoradiation for borderline resectable pancreatic cancer. J Surg Oncol 2011;104:155-61.
82. Gillmore R, Laurence V, Raouf S, et al. Chemoradiotherapy with or without induction chemotherapy for locally advanced pancreatic cancer: a U.K. multi-institutional experience. Clin Oncol (R Coll Radiol) 2010;22:564-9.
83. Schellenberg D, Kim J, Christman-Skieller C, et al. Singlefraction stereotactic body radiation therapy and sequential gemcitabine for the treatment of locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 2011;81:181-8.
84. Mahadevan A, Jain S, Goldstein M, et al. Stereotactic body radiotherapy and gemcitabine for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 2010;78:735-42.
85. Schellenberg D, Goodman KA, Lee F, et al. Gemcitabine chemotherapy and single-fraction stereotactic body radiotherapy for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 2008;72:678-86.
86. Didolkar MS, Coleman CW, Brenner MJ, et al. Image-guided stereotactic radiosurgery for locally advanced pancreatic adenocarcinoma results of first 85 patients. J Gastrointest Surg 2010;14:1547-59.
87. Rwigema JC, Parikh SD, Heron DE, et al. Stereotactic body radiotherapy in the treatment of advanced adenocarcinoma of the pancreas. Am J Clin Oncol 2011;34:63-9.